• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Francis Laura sold $661,368 worth of shares (38,504 units at $17.18) (SEC Form 4)

    5/9/25 7:01:42 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care
    Get the next $SIBN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FRANCIS LAURA

    (Last) (First) (Middle)
    C/O SI-BONE, INC.
    471 EL CAMINO REAL, SUITE 101

    (Street)
    SANTA CLARA CA 95050

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SI-BONE, Inc. [ SIBN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/07/2025 S(1) 38,504 D $17.1766(2) 302,958 I by Trust(3)
    Common Stock 506,761 D(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan.
    2. The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $17.00 to $17.59, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
    3. Shares by The David & Laura Francis Joint Rev Tr.
    4. Includes 442,987 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
    Remarks:
    /s/ Michael A. Pisetsky, Attorney-in-Fact for Laura A. Francis 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SIBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIBN

    DatePrice TargetRatingAnalyst
    8/6/2024$27.00 → $19.00Buy
    Needham
    3/28/2024$25.00Overweight
    Piper Sandler
    10/12/2022$20.00Buy
    Jefferies
    4/7/2022$34.00Overweight
    Cantor Fitzgerald
    3/1/2022$30.00 → $28.00Overweight
    Morgan Stanley
    1/18/2022$43.00 → $36.00Buy
    B of A Securities
    12/21/2021$35.00 → $30.00Buy
    Truist Securities
    11/9/2021$42.00 → $36.00Market Outperform
    JMP Securities
    More analyst ratings

    $SIBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

      SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id92Nrrn.cfm. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast wil

      5/6/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

      First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing growth of 26.6%Gross margin of 79.7%, representing an improvement of 80 basis pointsNet loss of $6.5 million, representing an improvement of 40.0%Positive adjusted EBITDA of $0.5 million$144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians

      5/5/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

      SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/ueassh6s. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for a

      4/14/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    $SIBN
    SEC Filings

    See more
    • SEC Form 144 filed by SI-BONE Inc.

      144 - SI-BONE, Inc. (0001459839) (Subject)

      5/7/25 4:21:02 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by SI-BONE Inc.

      10-Q - SI-BONE, Inc. (0001459839) (Filer)

      5/6/25 4:05:51 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SI-BONE, Inc. (0001459839) (Filer)

      5/5/25 4:12:45 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    $SIBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on SI-BONE with a new price target

      Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously

      8/6/24 8:40:50 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on SI-BONE with a new price target

      Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00

      3/28/24 7:47:33 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on SI-BONE with a new price target

      Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00

      10/12/22 9:04:16 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    $SIBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SIBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chief Executive Officer Francis Laura sold $661,368 worth of shares (38,504 units at $17.18) (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/9/25 7:01:42 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Maheshwari Anshul sold $599,033 worth of shares (33,287 units at $18.00), decreasing direct ownership by 12% to 237,006 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/9/25 7:00:36 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Director Dunn Jeffrey W sold $4,628 worth of shares (336 units at $13.78), decreasing direct ownership by 3% to 12,536 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/2/25 5:08:52 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      11/14/24 6:27:27 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      11/14/24 4:43:38 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      11/8/24 12:14:44 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    $SIBN
    Financials

    Live finance-specific insights

    See more
    • SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

      SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id92Nrrn.cfm. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast wil

      5/6/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

      First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing growth of 26.6%Gross margin of 79.7%, representing an improvement of 80 basis pointsNet loss of $6.5 million, representing an improvement of 40.0%Positive adjusted EBITDA of $0.5 million$144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians

      5/5/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

      SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/ueassh6s. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for a

      4/14/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    $SIBN
    Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

      Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help

      12/14/21 8:00:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

      SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa

      4/19/21 7:00:49 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care